MINUTES OF MEETING - December 6-7 
27 
Ms. King moved the proposal as it had appeared in the Federal 
Register (774/2). Dr. Gottesman proposed to amend the last 
paragraph of the proposal to read as follows: 
"At the same time, the committee regards the concept of 
voluntary compliance as experimental; in order to ensure 
further consideration after an initial trial period, the 
Committee agrees to conduct a review of the voluntary 
compliance program at its June 1980 meeting." 
Dr. Zaitlin favored this amendment which would eliminate the 
reference to a June 1, 1980, termination data. Dr. Novick said 
he preferred to retain a termination date in the proposal. The 
RAC accepted Dr. Gottesman' s amendment by a vote of ten in favor, 
seven opposed, with one abstention. A vote on 774/2 as amended 
by Dr. Gottesman, was accepted on this motion by a vote of fourteen 
in favor, three opposed, with one abstention. 
The text of the motion as adopted by the RAC is as follows: 
"Whereas it is desirable to establish a uniform standard of 
conduct for the performance of experiments involving recom- 
binant DNA techniques. 
And whereas the RAC has recommended mandatory compliance 
with the NIH Guidelines for non-federally funded 
institutions. 
And whereas there is currently no extent legal framework 
within which this can be effected. 
The RAC congratulates the Pharmaceutical Manufacturers 
Association and its member companies for the cooperative 
spirit that they have shown in agreeing to comply with the 
NIH Guidelines voluntarily under provisions of the supple- 
ment to the Guidelines adopted by the RAC at its meeting 
of September 6-7, 1979. 
At the same time, the committee regards the concept of 
voluntary compliance as experimental, in order to ensure 
future consideration after an initial trial period, the 
Committee agrees to conduct a review of the voluntary 
compliance program at its June 1980 meeting." 
[ 420 ] 
